RxDoctor Payments Data

Luis Schaeffer, MD

Internal Medicine · Cleveland, TXNPI 1376586230

Payments from drug & device makers

$763in general payments, 2019–2025

Across 36 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$145
  • Pfizer$96
  • Johnson & Johnson$78
  • Sunovion Pharmaceuticals Inc.$58
  • AstraZeneca$51
  • AbbVie$50
  • plus $287 from 10 others

What the payments were for

  • Food & beverage$67889%
  • Education$8511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$763 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$63,532
Medicare patients
90
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$148,002
EliquisApixaban87$83,789
TrulicityDulaglutide54$53,154
JanuviaSitagliptin Phosphate50$49,792
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$42,081
JardianceEmpagliflozin33$34,190
FarxigaDapagliflozin Propanediol22$22,606
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$21,527
LinzessLinaclotide22$20,800
JanumetSitagliptin Phos/Metformin Hcl13$17,796
TradjentaLinagliptin16$16,675
SymbicortBudesonide/Formoterol Fumarate51$14,195
Combivent RespimatIpratropium/Albuterol Sulfate26$12,790
Tresiba Flextouch U-100Insulin Degludec19$11,814
BrilintaTicagrelor12$11,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Levemir$36$154,327164 claims
PfizerEliquis$96$83,78987 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$41$63,65575 claims
AstraZenecaFarxiga, Symbicort, Brilinta$51$47,97785 claims
GSKTrelegy Ellipta$20$42,08159 claims
AbbVieLinzess$50$20,80022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Cleveland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →